Wainua trial failure sends AstraZeneca stock down 9% after drug fails to reduce cardiovascular deaths

AstraZeneca shares tumbled 9% on Tuesday after the company announced that its experimental heart drug Wainua failed to meet its primary goal in a late-stage trial. The UK pharmaceutical company said the drug, developed in partnership with Ionis, did not achieve a statistically significant reduction in cardiovascular deaths or recurring heart problems.

"UK pharmaceutical company says Wainua drug did not meet goal of reducing cardiovascular deaths"

ft.comAstraZeneca shares slide 9% after heart treatment disappoints in trial

According to finans.dk, the Phase 3 trial spanned over 140 weeks, and the drug ultimately "failed to statistically reduce deaths and recurring heart problems." The disappointing results sent shares down 9.1%, wiping out billions in market value as investors reassessed the drug's commercial prospects.

finans.dkAstrazeneca shares fall 9% after Wainua heart drug fails Phase 3 trial

Wainua was designed to lower a protein associated with cardiovascular risk, but the trial data showed no meaningful benefit over placebo. The Hindu Business Line reported that the treatment "could not reduce cardiovascular deaths or recurring heart problems," a stark outcome for a therapy that had shown promise in earlier studies.

AstraZeneca now faces questions about the future of its cardiovascular pipeline, as Wainua had been viewed as a potential blockbuster. The company will likely review additional data from the trial to determine next steps, including whether any subgroups showed a response.